A significant increase in ATG9A concentrations was evident in the kidneys of the CIS-treated Gal-3 wild-type mice when compared with Gal-3 wild-type sham control mice, signifying statistical significance (p < 0.001) (Figure 10D). Here, ATG9A is linked to in situ carcinoma.